Sono-Tek Corp. 10-Q Summary: Period Ended November 30, 2008
Business Context and Reporting Period
Sono-Tek Corporation (SONO) is a smaller reporting company specializing in ultrasonic atomizing nozzles and coating systems for electronics, medical, and industrial applications. This Form 10-Q covers the quarterly period ended November 30, 2008, and the nine-month period ended on that date. The company is actively pursuing a business development program to diversify into medical device (stent coating) and WideTrack coating markets.
Key Financial Metrics
| Metric | Nine Months Ended Nov 30, 2008 | Nine Months Ended Nov 30, 2007 | Three Months Ended Nov 30, 2008 | Three Months Ended Nov 30, 2007 |
|---|---|---|---|---|
| Net Sales | $4,808,012 | $4,207,724 | $1,582,010 | $1,560,558 |
| Gross Profit | $2,168,822 | $1,950,768 | $621,748 | $691,487 |
| Gross Margin | 45.1% | 46.4% | 39.3% | 44.3% |
| Operating Income (Loss) | $(688,937) | $(49,426) | $(366,499) | $3,517 |
| Net Income (Loss) | $(1,284,038) | $55,632 | $(976,284) | $23,649 |
| Cash and Equivalents (End of Period) | $1,256,999 | $1,952,627 | $1,256,999 | $1,952,627 |
| Working Capital | $3,018,080 | $4,059,720 | $3,018,080 | $4,059,720 |
| Debt (Line of Credit) | $250,000 | $0 | $250,000 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% year-over-year for the nine-month period, driven by additional sales of fluxer units, stent coaters, and precision coating units.
- Profitability Decline: The company shifted from a net income of $55,632 in the prior year period to a net loss of $1,284,038. The quarterly loss was $976,284 compared to income of $23,649.
- Expense Increases: Operating expenses rose significantly. Marketing and selling expenses increased $616,000 (nine months) due to sales force reorganization, increased trade show participation, and higher international commissions. R&D costs increased $71,000 due to added engineering personnel.
- Inventory Reserve: Gross margin for the quarter dropped to 39% from 44% due to a $75,000 increase in inventory reserves for slow-moving electronics parts.
- Tax Provision: A non-cash income tax expense of $611,586 was recorded due to an increased valuation reserve on deferred tax assets, reflecting uncertainty regarding the utilization of net operating loss carryforwards.
- Liquidity: Cash and cash equivalents decreased by approximately $1.08 million. Working capital declined by $1.04 million. The company drew $250,000 on its revolving line of credit.
Guidance, Outlook, and Risks
- Outlook: Management expects newer markets (medical, WideTrack) to be the basis for continued growth and future profitability, though success is not guaranteed. The company plans to continue investing in market and technology development.
- Capital Resources: The company has a $500,000 revolving line of credit (prime rate, 4% at period end), with $250,000 outstanding and $250,000 available. The line is collateralized by all company assets.
- Risks:
- Recovery of Misappropriated Funds: The company is attempting to recover the remaining balance of approximately $250,000 misappropriated by a former employee. A note exists but is fully reserved as collectibility is questionable.
- Market Conditions: General economic recession and slowdown in the electronics market have impacted inventory levels and margins.
- Valuation Reserve: Future adjustments to the deferred tax asset valuation reserve may occur based on the company's return to profitability.
Investor Verification Checklist
- Verify the collectibility status of the note receivable from the former employee regarding the $250,000 misappropriation.
- Monitor the utilization of the $250,000 remaining line of credit and the company's ability to meet the annual 30-day paydown requirement.
- Assess the trend in inventory reserves for electronics products given the market slowdown.
- Review the trajectory of marketing and selling expenses to determine if the business development program yields a return on investment in future quarters.
- Confirm the status of the deferred tax asset valuation reserve and the likelihood of utilizing net operating loss carryforwards.